文献速递肝病消化道肿瘤与早癌

局部乳酸脱氢酶抑制增强肝细胞癌治疗并克服耐药

Locoregional lactate dehydrogenase inhibition potentiates therapy and overcomes treatment resistance in hepatocellular carcinoma.
PubMed 文献 · Hepatology · 2026-04-30

本研究探讨经动脉栓塞(TAE)诱导的缺血应激能否使肝细胞癌(HCC)对乳酸脱氢酶(LDH)抑制剂NCATS-SM1441增敏。体外实验显示缺血条件诱导LDHA表达和糖酵解通量,增加对LDH抑制的敏感性;在大鼠HCC模型中,动脉内给予NCATS-SM1441联合TAE可增加瘤内药物积累、减少全身暴露、协同抑制乳酸生成、促进肿瘤坏死并显著延长局部无进展生存期。结论提示TAE可创造可靶向的糖酵解依赖,联合LDH抑制克服代谢抑制剂单药治疗的局限。

要点

  • 缺血应激诱导HCC糖酵解依赖,增加对LDH抑制的敏感性。
  • 动脉内LDH抑制剂联合TAE协同促进肿瘤坏死并延长生存。
  • 联合治疗增加瘤内药物积累并减少全身暴露。

核心结论

  • TAE可重塑肿瘤微环境创造可靶向的糖酵解依赖,联合LDH抑制增强局部控制与生存且全身毒性最小。

研究设计与样本

  • 体外用人HCC细胞系在完全或缺血(类TAE)条件下暴露于LDH抑制剂NCATS-SM1441,评估葡萄糖/乳酸通量、ATP水平和活力。
  • 体内用二乙基亚硝胺(DEN)诱导的大鼠HCC模型,经动脉给予NCATS-SM1441、TAE或两者联合,用质谱成像、组织病理学、T2加权MRI和生存指标分析药物分布、肿瘤代谢、坏死和生存。

主要发现

  • 缺血条件诱导LDHA表达和糖酵解通量,增强对LDH抑制的易感性。
  • 栓塞前经动脉给予NCATS-SM1441增加瘤内药物积累并减少全身暴露。
  • 联合治疗协同抑制乳酸生成、促进肿瘤坏死并显著延长局部无进展生存期。

临床怎么用

  • 支持将代谢靶向药物与局部治疗(LRT)整合用于不可切除HCC。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: Metabolic inhibitors have demonstrated limited efficacy for cancer therapy due to metabolic plasticity and systemic toxicity. Locoregional therapies (LRT), such as transarterial embolization (TAE) or transarterial chemoembolization (TACE), generate ischemic stress that reprograms the tumor microenvironment (TME) toward glycolytic dependency, creating an opportunity to sensitize hepatocellular carcinoma (HCC) to metabolic inhibition. This study investigated whether pharmacologic inhibition of lactate dehydrogenase (LDH) with NCATS-SM1441 could exploit TAE-induced metabolic vulnerabilities to improve therapeutic efficacy in HCC. APPROACH AND RESULTS: Human HCC cell lines were exposed to replete or ischemic (TAE-like) conditions and treated with the LDH inhibitor NCATS-SM1441. Glucose/lactate flux, adenosine triphosphate (ATP) levels, and viability were assessed. In vivo, a diethylnitrosamine (DEN)-induced rat HCC model was treated with intra-arterial NCATS-SM1441, TAE, or their combination. Drug distribution, tumor metabolism, necrosis, and survival were analyzed using mass spectrometry imaging, histopathology, T2-weighted magnetic resonance imaging (MRI), and survival metrics. Ischemic conditions induced LDHA expression and glycolytic flux, enhancing susceptibility to LDH inhibition. The combination of intra-arterial NCATS-SM1441 before embolization increased intratumoral drug accumulation, reduced systemic exposure, and synergized with TAE to suppress lactate production, promote tumor necrosis, and significantly extend local progression-free survival. CONCLUSIONS: TAE conditions the TME to create a therapeutically targetable glycolytic dependency. Combining TAE with LDH inhibition overcomes key limitations of metabolic inhibitors as monotherapies, enhancing local control and survival with minimal systemic toxicity, supporting integration of metabolism-targeted agents with LRT for unresectable HCC.

来源:Hepatology,查看原文。版权归原作者所有。

引用

  1. Boehmler DJ, Baron RJ, Brain JA, et al. Locoregional lactate dehydrogenase inhibition potentiates therapy and overcomes treatment resistance in hepatocellular carcinoma. Hepatology. 2026. PMID: 42059877. doi:10.1097/HEP.0000000000001775

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。